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Introduction {#sec005}
============

Bone represents one of the most common sites for cancer spread, especially in patients with breast, prostate, or lung malignancies.\[[@pone.0228360.ref001], [@pone.0228360.ref002]\] Bone metastases are a significant source of morbidity, decreased performance status, and impaired quality of life. Moreover, the presence of bone metastases typically portends a poor prognosis, with a median overall survival (OS) of 6−7 months.\[[@pone.0228360.ref003]\]

Several factors--including clinical stage, patient demographics, and tumor histology--have been shown to affect the OS of patients with bone metastases.\[[@pone.0228360.ref004]\] Notably, sex disparities have been reported in the survival of patients with metastatic spread to the bone--with mortality rate ratios being significantly higher in males than in females for most malignancies.\[[@pone.0228360.ref005]\] Women also have a higher total adiposity than men, with a preponderance of subcutaneous adipose tissue. In contrast, men typically tend to accumulate visceral adipose tissue.\[[@pone.0228360.ref006]\] Subcutaneous and visceral adipose tissue indices (SATI and VATI, respectively) may influence the clinical outcomes of patients with cancer in a sex-dependent manner. \[[@pone.0228360.ref007]\]

Previous studies have reported a significant prognostic impact of SATI and VATI in different solid tumors, including advanced renal cell carcinoma, hepatocellular carcinoma, and pancreatic cancer,\[[@pone.0228360.ref008]--[@pone.0228360.ref010]\] although there has been some discrepant findings and the therapeutic implications of these observations have not been fully elucidated \[[@pone.0228360.ref011]\].

The aim of this study was to investigate whether measures of regional adiposity--including SATI and VATI--can be associated with overall survival (OS) in Taiwanese patients with bone metastases who were referred for radiotherapy (RT).

Materials and methods {#sec006}
=====================

Study patients {#sec007}
--------------

The present study was designed as a retrospective review of prospectively collected data and was conducted in a radiation oncology setting. Between March 2005 and August 2013, a total of 1654 Taiwanese patients with bone metastases were consecutively referred for RT to the Chang Gung Memorial Hospital. All of them had a histology-proven diagnosis of cancer and underwent computed tomography (CT) imaging within 30 days of the initial assessment. The diagnosis of bone metastases was based on the results of bone scintigraphy, X-ray, CT, or magnetic resonance imaging. Patients were excluded in presence of the following criteria: age \<18 years, unavailable CT scans within two weeks before the start of RT, or lack of measures of weight and height within two weeks of enrolment. A total of 374 cases met the exclusion criteria, resulting in a final study sample of 1280 patients. The study protocol was reviewed and approved by the Institution Review Board of the Chang Gung Memorial Hospital (approval number: IRB: 201701224B0). Owing to the retrospective nature of the analysis, the need for informed consent was waived. Data collection from electronic medical records was supervised by an experienced nurse and a radiation oncologist.

CT-based body composition analysis {#sec008}
----------------------------------

In keeping with previous methodology,\[[@pone.0228360.ref012]\] single-slice CT imaging at level L3 was used to analyze adiposity. SATI and VATI were identified according to Hounsfield units (HU) (from -190 to -30 HU for SATI and from -29 to 150 HU for VATI, respectively). The tissue cross-sectional areas (expressed in cm^2^) were calculated automatically by the CT software after normalization for patient height. SATI, VATI, total adipose tissue, and skeletal muscle indexes were expressed in cm^2^ m^-2^. All adiposity measures were taken in the two weeks preceding the start of RT.

Variable definition {#sec009}
-------------------

Owing to the lack of a commonly accepted standard, SATI, VATI, and skeletal muscle indices were dichotomized according to median values measured at L3. OS was defined as the time elapsed from the start of RT for bone metastases to the date of death. Body mass index (BMI) was categorized as follows: underweight (BMI \<18.5 kg/m^2^), normal weight (BMI: 18.5--24.99 kg/m^2^), overweight (BMI: 25--29.99 kg/m^2^), and obese (BMI ≥30 kg/m^2^). Equivalent doses in 2-Gy fraction (EQD2Gy) were used to express different total radiation doses in terms of amount and number of fractions. The time to metastases (calculated from the time of diagnosis of primary cancer to the identification of distant metastases) was categorized in ≤ 1 year *versus* \>1 year. Metastases were considered multiple in presence of simultaneous involvement of at least two organs or different parts of skeleton (e.g., sternum and sacrum). The use of systemic therapy was investigated in the timeframe ranging from 1 month before RT to the date of the last follow-up. Other variables of interest were previously described.\[[@pone.0228360.ref013]\] The presence of comorbidities was dichotomized (yes *versus* no) according to the Charlson comorbidity index. Employment status was classified into three categories using the Registrar General's Social Class (RGSC) scheme, as follows: unemployed, low-wage employed, and high-wage employed. Education status was categorized as high *versus* low (junior high school and above *versus* elementary school and below). The patient's place of residence was dichotomized as either rural or urban (population density below or above 800 persons per km^2^, respectively). Risky oral habits were classified as follows: cigarette smoking (smoked ≥100 in lifetime *versus* \< 100 cigarettes in lifetime and no current smoking), betel quid chewing (current/former *versus* never), and alcohol drinking (current/former *versus* never).

Statistical analysis {#sec010}
--------------------

Continuous variables were compared using the Student's *t*-test, whereas the Pearson's chi-square test was used for categorical variables. The associations between the study variables (including indices of adiposity) and OS were investigated using univariate and multivariate Cox proportional hazard ratio analyses. Results were expressed as hazard ratios (HRs) with their 95% confidence interval (CIs). We also categorized patients according to SATI and VATI values (high *versus* low, with high values serving as references). Survival plots were constructed with the Kaplan-Meier method (log-rank test).Two-tailed P values \<0.05 were considered statistically significant. Owing to the exploratory nature of the study, the Bonferroni's correction was not applied.

Results {#sec011}
=======

Patient characteristics {#sec012}
-----------------------

The general characteristics of the study patients are summarized in [Table 1](#pone.0228360.t001){ref-type="table"}. Of the 1280 participants, 1237 were followed up until death, whereas the remaining 43 were censored on the date last known to be alive. The study cohort included 740 (57.8%) men and 540 (42.2%) women. The most common primary cancer site was the lung (35% in both sexes), and there were 897 (70%) patients with an ECOG performance status of 0−1. The interval between the diagnosis of primary cancer and the detection of metastases was 0.11 months in women (95% CI: 0−15.64 months) and 0.04 months (95% CI: 0−13.50 months) in men, respectively. [Table 1](#pone.0228360.t001){ref-type="table"} shows the results pertaining to adiposity indices. Men had higher skeletal muscle and VATI than women, whereas SATI was higher in women.

10.1371/journal.pone.0228360.t001

###### Patient characteristics according to the subcutaneous and visceral adiposity status.

![](pone.0228360.t001){#pone.0228360.t001g}

                                     SATI                    VATI                                                                                                                                                                                         
  ---------------------------------- ----------------------- ---------------------- ----------------------- ---------------------- ----------------------------------------------- ------------------------ ---------------------- ---------------------- -----------------------------------------------
  **Number of patients**             640 (50.0%)             640 (50.0%)            1280 (100%)                                    640 (50.0%)                                     640 (50.0%)              1280 (100%)                                   
  **SATI**                                                                                                                                                                                                                                                
                                     Low                                                                                                                                           455 (71.1%)              185 (28.9%)            640 (50.0%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     High                                                                                                                                          185 (28.9%)              455 (71.1%)            640 (50.0%)            
                                     Median                  8.15 (0.01--15.48)     27.77 (15.50--148.77)   15.49 (0.01--148.77)   \<0.001[^b^](#t001fn003){ref-type="table-fn"}   9.93 (0.01--71.92)       23.30 (1.24--148.77)   15.49 (0.01--148.77)   \<0.001[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean ± SD, cm^2^/m^2^   7.96±4.58              33.42±17.87             20.69±18.22                                                            12.81±11.92              28.57±19.96            20.69±18.22            
  **VATI**                                                                                                                                                                                                                                                
                                     Low                     455 (71.1%)            185 (28.9%)             640 (50.0%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}                                                                          
                                     High                    185 (28.9%)            455 (71.1%)             640 (50.05%)                                                                                                                                  
                                     Median                  4.74 (0.02--72.53)     15.59 (0.40--93.34)     9.84 (0.02--93.34)     \<0.001[^b^](#t001fn003){ref-type="table-fn"}   3.70 (0.02--9.83)        19.35 (9.84--93.34)    9.84 (0.02--93.34)     \<0.001[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    8.10±9.39              18.35±13.19             13.23±12.54                                                            4.07±2.92                22.39±11.75            13.23±12.54            
  **Muscle index**                                                                                                                                                                                                                                        
                                     Low                     293 (45.8%)            347 (54.2%)             640 (50.0%)            0.003[^a^](#t001fn002){ref-type="table-fn"}     333 (52.0%)              307 (48.0%)            640 (50.0%)            0.162[^a^](#t001fn002){ref-type="table-fn"}
                                     High                    347 (54.2%)            293 (45.8%)             640 (50.0%)                                                            307 (48.0%)              333 (52.0%)            640 (50.0%)            
                                     Median                  17.23 (4.02--49.49)    16.01 (6.44--93.90)     16.61 (4.02--93.90)    0.015[^b^](#t001fn003){ref-type="table-fn"}     16.41 (4.02--43.93)      16.89 (6.44--93.90)    16.61 (4.02--93.9)     0.063[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    17.78±5.59             16.96±6.28              17.37±5.95                                                             17.06±5.65               17.68±6.23             17.37±5.95             
  **Age group, years**                                                                                                                                                                                                                                    
                                     \<59.5                  318 (49.7%)            313 (48.9%)             631 (49.3%)            0.823[^a^](#t001fn002){ref-type="table-fn"}     376 (58.8%)              255 (39.8%)            631 (49.3%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     ≥59.5                   322 (50.3%)            327 (51.1%)             649 (50.7%)                                                            264 (41.3%)              385 (60.2%)            649 (50.7%)            
                                     Median                  59.67 (19.54--95.57)   59.83 (21.98--87.05)    59.73 (19.54--95.57)   0.503[^b^](#t001fn003){ref-type="table-fn"}     56\. 79 (19.54--95.57)   63.01 (27.9--90.45)    59.73 (19.54--95.57)   \<0.001[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    60.55±13.16            60.08±12.11             60.32±12.64                                                            57.59±12.94              63.04±11.73            60.32±12.64            
  **Sex**                                                                                                                                                                                                                                                 
                                     Female                  152 (23.8%)            388 (60.6%)             540 (42.2%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}   287 (44.8%)              253 (39.5%)            540 (42.2%)            0.062[^a^](#t001fn002){ref-type="table-fn"}
                                     Male                    488 (76.3%)            252 (39.4%)             740 (57.8%)                                                            353 (55.2%)              387 (60.5%)            740 (57.8%)            
  **Performance status**                                                                                                                                                                                                                                  
                                     ECOG 0--1               428 (66.9%)            469 (73.3%)             897 (70.1%)            0.015[^a^](#t001fn002){ref-type="table-fn"}     444 (69.4%)              453 (70.8%)            897 (70.1%)            0.625[^a^](#t001fn002){ref-type="table-fn"}
                                     ECOG 2--4               212 (33.1%)            171 (26.7%)             383 (29.9%)                                                            196 (30.6%)              187 (29.2%)            383 (29.9%)            
  **Onset of metastasis**                                                                                                                                                                                                                                 
                                     ≤ 1 year                470 (73.4%)            430 (67.2%)             900 (70.3%)            0.017[^a^](#t001fn002){ref-type="table-fn"}     455 (71.1%)              445 (69.5%)            900 (70.3%)            0.541[^a^](#t001fn002){ref-type="table-fn"}
                                     \> 1 years              170 (26.6%)            210 (32.8%)             380 (29.7%)                                                            185 (28.9%)              195 (30/5%)            380 (29.7%)            
                                     Median                  0.08 (0--13.50)        0.04 (0--15.64)         0.05 (0--15.64)        0.006[^b^](#t001fn003){ref-type="table-fn"}     0.08 (0--15.64)          0.04 (0--15.64)        0.05 (0--15.64)        0.652[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    1.04±2.03              1.40±2.56               1.22±2.32                                                              1.19±2.28                1.25±2.36              1.22±2.32              
  **Site of metastasis**                                                                                                                                                                                                                                  
                                     Bone                    543 (84.8%)            542 (84.7%)             1085 (84.8%)           0.943                                           524 (81.9%)              561 (87.7%)            1085 (84.8%)           0.007
                                     Brain                   17 (2.7%)              19 (3.0%)               36 (2.8%)                                                              25 (3.9%)                11 (1.7%)              36 (2.8%)              
                                     Others                  80 (12.5%)             79 (12.3%)              159 (12.4%)                                                            91 (14.2%)               68 (10.6%)             159 (12.4%)            
  **Multiple metastases**                                                                                                                                                                                                                                 
                                     No                      121 (18.9%)            124 (19.4%)             245 (19.1%)            0.832[^a^](#t001fn002){ref-type="table-fn"}     120 (18.8%)              125 (19.5%)            245 (19.1%)            0.776[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     519 (81.1%)            516 (80.6%)             1035 (80.9%)                                                           520 (81.3%)              515 (80.5%)            1035 (80.9%)           
  **Site of primary cancer**                                                                                                                                                                                                                              
                                     Lung cancer             253 (39.5%)            222 (34.7%)             475 (37.1%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}   232 (36.3%)              243 (38.0%)            475 (37.1%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     Hepatoma                75 (11.7%)             60 (9.4%)               135 (10.5%)                                                            75 (11.7%)               60 (9.4%)              135 (10.5%)            
                                     Breast cancer           26 (4.1%)              90 (14.1%)              116 (9.1%)                                                             56 (8.8%)                60 (9.4%)              116 (9.1%)             
                                     Prostate cancer         39 (6.1%)              53 (8.3%)               92 (7.2%)                                                              21 (3.3%)                71 (11.1%)             92 (7.2%)              
                                     Rectal cancer           34 (5.3%)              43 (6.7%)               77 (6.0%)                                                              40 (6.3%)                37 (5.8%)              77 (6.0%)              
                                     Others                  213 (33.3%)            172 (26.9%)             385 (30.1%)                                                            216 (33.8%)              169 (26.4%)            385 (30.1%)            
  **EQD**~**2Gy**~                                                                                                                                                                                                                                        
                                     \<32.5                  337 (52.7%)            279 (43.6%)             616 (48.1%)            0.001[^a^](#t001fn002){ref-type="table-fn"}     325 (50.8%)              291 (45.5%)            616 (48.1%)            0.065[^a^](#t001fn002){ref-type="table-fn"}
                                     ≥32.5                   303 (47.3%)            361 (56.4%)             664 (51.9%)                                                            315 (49.2%)              349 (54.5%)            664 (51.9%)            
                                     Median                  31.25 (1.44--70.00)    32.50 (3.25--84.00)     32.50 (1.44--84.00)    \<0.001[^b^](#t001fn003){ref-type="table-fn"}   31.98 (1.83--70.00)      32.50 (1.44--84.00)    32.50 (1.44--84.00)    0.484[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    28.14±10.99            30.66±10.70             29.40±10.91                                                            29.19±11.29              29.62±10.52            29.40±10.91            
  **Systemic therapy**                                                                                                                                                                                                                                    
                                     No                      266 (41.6%)            164 (25.6%)             430 (33.6%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}   238 (37.2%)              192 (30.0%)            430 (33.6%)            0.008[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     374 (58.4%)            476 (74.4%)             850 (66.4%)                                                            402 (62.8%)              448 (70.0%)            850 (66.4%)            
  **Comorbidities**                                                                                                                                                                                                                                       
                                     No                      296 (46.3%)            256 (40.0%)             552 (43.1%)            0.028[^a^](#t001fn002){ref-type="table-fn"}     328 (51.2%)              224 (35.0%)            552 (43.1%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     344 (53.8%)            384 (60.0%)             728 (56.9%)                                                            312 (48.8%)              416 (65.0%)            728 (56.9%)            
  **Employment status**                                                                                                                                                                                                                                   
                                     High                    152 (23.8%)            142 (22.2%)             294 (23.0%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}   152 (23.8%)              142 (22.2%)            294 (23.0%)            0.152[^a^](#t001fn002){ref-type="table-fn"}
                                     Low                     275 (43.0%)            169 (26.4%)             444 (34.7%)                                                            234 (36.6%)              210 (32.8%)            444 (34.7%)            
                                     None                    213 (33.3%)            329 (51.4%)             542 (42.3%)                                                            254 (39.7%)              288 (45.0%)            542 (42.3%)            
  **Education level**                                                                                                                                                                                                                                     
                                     None/primary school     311 (48.6%)            344 (53.8%)             655 (51.2%)            0.074[^a^](#t001fn002){ref-type="table-fn"}     291 (45.5%)              364 (56.9%)            655 (51.2%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     High school             329 (51.4%)            296 (46.3%)             625 (48.8%)                                                            349 (54.5%)              276 (43.1%)            625 (48.8%)            
  **Place of residence**                                                                                                                                                                                                                                  
                                     Urban                   351 (54.8%)            345 (53.9%)             696 (54.4%)            0.779[^a^](#t001fn002){ref-type="table-fn"}     364 (56.9%)              332 (51.9%)            696 (54.4%)            0.082[^a^](#t001fn002){ref-type="table-fn"}
                                     Rural                   289 (45.2%)            295 (46.1%)             584 (45.6%)                                                            276 (43.1%)              308 (48.1%)            584 (45.6%)            
  **Cigarette smoking**                                                                                                                                                                                                                                   
                                     No                      270 (42.2%)            455 (71.1%)             725(56.6%)             \<0.001[^a^](#t001fn002){ref-type="table-fn"}   356 (55.6%)              369 (57.7%)            725 (56.6%)            0.499[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     370 (57.8%)            185(28.9%)              555 (43.4%)                                                            284 (44.4%)              271 (42.3%)            555 (43.4%)            
  **Betel quid chewing**                                                                                                                                                                                                                                  
                                     No                      511 (79.8%)            578 (90.3%)             1089 (85.1%)           \<0.001[^a^](#t001fn002){ref-type="table-fn"}   538 (84.1%)              551 (86.1%)            1089 (85.1%)           0.347[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     129 (20.2%)            62 (9.7%)               191 (14.9%)                                                            102 (15.9%)              89 (13.9%)             191 (14.9%)            
  **Alcohol drinking**                                                                                                                                                                                                                                    
                                     No                      420 (65.6%)            531 (83.0%)             951 (74.3%)            \<0.001[^a^](#t001fn002){ref-type="table-fn"}   468 (73.1%)              483 (75.5%)            951 (74.3%)            0.338[^a^](#t001fn002){ref-type="table-fn"}
                                     Yes                     220 (34.4%)            109 (17.0%)             329 (25.7%)                                                            172 (26.9%)              157 (24.5%)            329 (25.7%)            
  **Days of metastases treatment**                                                                                                                                                                                                                        
                                     ≤12                     360 (56.3%)            311 (48.6%)             671 (52.4%)            0.007[^a^](#t001fn002){ref-type="table-fn"}     328 (51.2%)              343 (53.6%)            671 (52.4%)            0.433[^b^](#t001fn003){ref-type="table-fn"}
                                     ≥13                     280 (43.8%)            329 (51.4%)             609 (47.6%)                                                            312 (48.8%)              297 (46.4%)            609 (47.6%)            
                                     Median                  11.50 (1--93)          13.00(1--67)            12.00(1--93)           \<0.001[^b^](#t001fn003){ref-type="table-fn"}   12.00 (1--93)            12.00(1--67)           12.00(1--93)           0.984[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    11.60±7.98             13.59 ±8.86             12.59±8.49                                                             12.59±8.91               12.60±8.05             12.59±8.49             
  **Metastasis treatment period**                                                                                                                                                                                                                         
                                     ≤2009                   331 (51.7%)            298 (46.6%)             629 (49.1%)            0.074[^a^](#t001fn002){ref-type="table-fn"}     312 (48.8%)              317 (49.5%)            629 (49.1%)            0.823[^a^](#t001fn002){ref-type="table-fn"}
                                     ≥2010                   309 (48.3%)            342 (53.4%)             651 (50.9%)                                                            328 (51.2%)              323 (50.5)             651 (50.9%)            
  **Body mass index, kg/m**^**2**^                                                                                                                                                                                                                        
                                     Underweight             116 (18.1%)            4 (0.6%)                120 (9.4%)             \<0.001[^a^](#t001fn002){ref-type="table-fn"}   118 (18.4%)              2 (0.3%)               120 (9.4%)             \<0.001[^a^](#t001fn002){ref-type="table-fn"}
                                     Normal weight           478 (74.7%)            344 (53.8%)             822 (64.2%)                                                            465 (72.7%)              357 (55.8%)            822 (64.2%)            
                                     Overweight              45 (7.0%)              242 (37.8%)             287 (22.4%)                                                            55 (8.6%)                232 (36.3%)            287 (22.4%)            
                                     Obese                   1 (0.2%)               50 (7.9%)               51 (4.0%)                                                              2 (0.3%)                 49 (7.7%)              51 (4.0%)              
                                     Median                  21.01 (13.34--20.65)   24.78 (16.98--38.73)    22.86 (13.34--38.73)   \<0.001[^b^](#t001fn003){ref-type="table-fn"}   21.01 (13.34--30.65)     24.68 (16.98--38.73)   22.86 (13.34--38.73)   \<0.001[^b^](#t001fn003){ref-type="table-fn"}
                                     Mean                    21.12±2.74             25.08±3.32              23.10±3.63                                                             21.12±2.74               25.08±3.32             23.10± 3.63            

Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; EQD2 Gy, equivalent doses in 2-Gy fractions; SATI, subcutaneous adipose tissue index; VATI, visceral adipose tissue index.

^a^Chi-square test

^b^ANOVA test

Survival analysis {#sec013}
-----------------

The median follow-up time for the 43 surviving patients was 78.28 months (range: 0.789−147.25 months). The median OS after RT was 6.03 months (range: 0.03−147.25 months). The 6-, 12-, 24-, and 48-month OS rates in women and men were 41.4%/61.8%, 23.6% /43.2%, 9.8%/22.6%, and 3.8%/11.2%, respectively. The median OS was 9.53 months (range: 0.10−137.42 months) in women and 4.7 months (range: 0.30−147.25) in men.

SATI values ≥11.63 cm^2^ in men and ≥25.21 cm^2^ in women were considered as high. Similarly, VATI values ≥10.46 cm^2^ in men and ≥8.96 cm^2^ in women were regarded as elevated. The median OS in the high and low SATI groups was 27.77 months (range: 15.50−148.77 months) and 8.15 months (range: 0.01−15.48 months), respectively. The median OS in the high and low VATI groups was 19.35 months (range: 9.84−93.34 months) and 3.70 months (range: 0.02−9.83 months), respectively.

The results of univariate and multivariate analyses are presented in [Table 2](#pone.0228360.t002){ref-type="table"}. The following variables were independently associated with OS in multivariate analysis: SATI, VATI, sex, performance status, primary tumor site, more than one metastatic site, ECOG performance status, EQD2Gy, systemic therapy, education, days of metastases treatment, and time to metastases ([Table 2](#pone.0228360.t002){ref-type="table"}).

10.1371/journal.pone.0228360.t002

###### Univariate and multivariate analysis of overall survival.

![](pone.0228360.t002){#pone.0228360.t002g}

                                                               Univariate analysis                           Multivariable analysis             
  ------------------------------------------------------------ ---------------------- ---------------------- ------------------------ --------- --
  Number of patients = 1280                                    HR (95% CI)            P value                HR (95% CI)              P value   
  SATI (high *versus* low)                                     0.551 (0.492--0.618)   \<0.001                0.696 (0.606--0.800)     \<0.001   
  VATI (high *versus* low)                                     0.756 (0.676--0.846)   \<0.001                0.870 (0.764--0.992)     0.037     
  Muscle index (high *versus* low)                             1.042 (0.932--1.165)   0.470                                                     
  Age group (≥59.5 *versus* \<59.5 years)                      1.186 (1.061--1.327)   0.003                  0.972 (0.848--1.113)     0.679     
  Sex (male *versus* female)                                   1.579 (1.408--1.770)   \<0.001                1.186 (1.010--1.393)     0.037     
  ECOG performance status (2--4 *versus* 0--1)                 1.257 (1.113--1.420)   \<0.001                1.305 (1.153--1.478)     \<0.001   
  Multiple metastases (yes *versus* no)                        1.414 (1.223--1.635)   \<0.001                1.350 (1.165--1.565)     \<0.001   
  Site of primary cancer (lung *versus* other sites)           0.816 (0.727--0.916)   0.001                  0.813 (0.716--0.922)     0.001     
  EQD~2Gy~ (≥32.5 *versus* \<32.5)                             0.651 (0.582--0.729)   \<0.001                0.802 (0.695--0.925)     0.002     
  Systemic therapy (yes *versus* no)                           0.584 (0.519--0.658)   \<0.001                0.621 (0.546--0.706)     \<0.001   
  Comorbidities (yes *versus* no)                              1.120 (1.000--1.253)   0.049                  1.065 (0.948--1.198)     0.288     
  Education level (high school *versus* none/primary school)   0.864 (0.772--0.966)   0.010                  0.869 (0.763--0.989)     0.033     
  Cigarette smoking (yes *versus* no)                          1.432 (1.279--1.603)   \<0.001                1.092 (0.934--1.276)     0.272     
  Betel quid chewing (yes *versus* no)                         1.331 (1.139--1.555)   \<0.001                0.964 (0.804--1.155)     0.689     
  Alcohol drinking (yes *versus* no)                           1.373 (1.209--1.560)   \<0.001                1.148 (0.989--1.332)     0.069     
  Days of metastasis treatment (≥13 *versus* ≤12)              0.704 (0.629--0.787)   \<0.001                0.864 (0.750--0.996)     0.044     
  Onset of metastasis (\>1 year *versus* ≤1 year)              0.800 (0.708--0.904)   \<0.001                0.913 (0.801--1.041)     0.175     
  Place of residence (urban *versus* rural)                    0.985 (0.881--1.102)   0.795                                                     
  Site of metastasis                                                                  0.216                                                     
                                                               Bone                   1.340 (0.957--1.877)   0.089                              
                                                               Brain                  0.974 (0.821--1.156)   0.765                              
  Employment status                                                                   0.556                                                     
      (low *versus* high)                                      1.084 (0.932--1.260)   0.294                                                     
      (none *versus* high)                                     1.034 (0.895--1.195)   0.652                                                     
  Metastases treatment period (≥2010 *versus* ≤2009)           0.990 (0.886--1.107)   0.866                                                     
  Body mass index (\>25 *versus* ≤25 kg/m^2^)                  0.755 (0.664--0.857)   \<0.001                                                   

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EQD2 Gy, equivalent doses in 2-Gy fractions; SATI, subcutaneous adipose tissue index; VATI, visceral adipose tissue index. An L3 subcutaneous adipose tissue index ≥11.63 cm^2^ m^-2^ in males and ≥25.21 cm^2^ m^-2^ in females was considered as high. An L3 visceral adipose tissue index ≥10.46 cm^2^ m^-2^ in males and ≥8.96 cm^2^ m^-2^ in females was considered as high.

Prognostic significance of SATI and VATI {#sec014}
----------------------------------------

We subsequently examined the prognostic impact of SATI and VATI by classifying patients into high *versus* low categories. Kaplan-Meier analysis revealed no differences in OS between the high SATI/high VATI group (median survival: 9.37 months) and high SATI/low VATI group (median survival: 9.43 months; P = 0.303; [Table 3](#pone.0228360.t003){ref-type="table"}). The lowest OS (3.97 months) was observed in the low SATI/low VATI group ([Fig 1](#pone.0228360.g001){ref-type="fig"}; [Table 3](#pone.0228360.t003){ref-type="table"}).

![Kaplan-Meier estimates of overall survival in patients with bone metastases stratified according to subcutaneous adiposity (high *versus* low) and visceral adiposity (high *versus* low).](pone.0228360.g001){#pone.0228360.g001}

10.1371/journal.pone.0228360.t003

###### Multivariate Cox regression analysis of overall survival in patients stratified according to subcutaneous adiposity and visceral adiposity.

![](pone.0228360.t003){#pone.0228360.t003g}

  Subgroup              No. of patients   Median survival time (95% CI)   HR                     P value
  --------------------- ----------------- ------------------------------- ---------------------- -----------------------------------------------
  High SATI/high VATI   455               9.370 (8.116--10.624)                                  \<0.001[^a^](#t003fn002){ref-type="table-fn"}
  High SATI/low VATI    185               9.436 (7.129--11.742)           1.097 (0.920--1.307)   0.303
  Low SATI/high VATI    185               4.603 (3.657--5.548)            1.882 (1.580--2.242)   \<0.001[^a^](#t003fn002){ref-type="table-fn"}
  Low SATI/low VATI     455               3.978 (3.362--4.594)            1.854 (1.622--2.121)   \<0.001[^a^](#t003fn002){ref-type="table-fn"}

Abbreviations: CI, confidence interval; HR, hazard ratio; SATI, subcutaneous adipose tissue index; VATI, visceral adipose tissue index.

^a^Chi-square test

^b^ANOVA test.

Prognostic stratification according to sex and body composition {#sec015}
---------------------------------------------------------------

Thereafter, both sex and SATI values were taken into account to construct four different groups. We specifically selected SATI owing to its higher prognostic value in multivariate analysis. A total of four groups were identified (male/high SATI; female/high SATI; male/low SATI; female/low SATI), with the most favorable survival figures being evident in the female/high SATI group (median OS: 11.21 months; 95% CI: 9.434−12.988 months; P\<0.001 *versus* other groups). The less favorable OS survival (median: 3.847 months; 95% CI: 3.391−4.302 months) was observed in the male/low SATI group ([Fig 2](#pone.0228360.g002){ref-type="fig"}; [Table 4](#pone.0228360.t004){ref-type="table"}).

![Kaplan-Meier estimates of overall survival in patients with bone metastases stratified according to subcutaneous adiposity (high *versus* low) and sex (female *versus* male).](pone.0228360.g002){#pone.0228360.g002}

10.1371/journal.pone.0228360.t004

###### Multivariate Cox regression analysis of overall survival in patients stratified according to sex and subcutaneous adiposity.

![](pone.0228360.t004){#pone.0228360.t004g}

  Subgroup                No. of patients   Median survival time (95%CI)   HR                     P value
  ----------------------- ----------------- ------------------------------ ---------------------- -----------------------------------------------
  Female with high SATI   388               11.211 (9.434--12.988)                                \<0.001[^a^](#t004fn002){ref-type="table-fn"}
  Female with low SATI    152               5.293 (3.084--7.503)           1.604 (1.324--1.942)   \<0.001[^a^](#t004fn002){ref-type="table-fn"}
  Male with high SATI     252               6.773 (5.481--8.064)           1.312 (1.115--1.545)   \<0.001[^a^](#t004fn002){ref-type="table-fn"}
  Male with low SATI      488               3.847 (3.391--4.302)           2.182 (1.899--2.507)   \<0.001[^a^](#t004fn002){ref-type="table-fn"}

Abbreviations: CI, confidence interval; HR, hazard ratio; SATI, subcutaneous adipose tissue index.

^a^Chi-square test

^b^ANOVA

Discussion {#sec016}
==========

The results of this retrospective analysis of prospectively collected data can be summarized as follows: 1) high SATI and VATI were independently associated with a better OS in a sample of Taiwanese patients with bone metastases, with the former showing a stronger relationship; 2) the most favorable OS was observed in women with high SATI. Although we observed associations--and not prediction or causation--our study adds to the growing literature investigating adiposity in relation to clinical outcomes of patients with malignancies.\[[@pone.0228360.ref013]--[@pone.0228360.ref015]\]

Currently, the association of indices of adiposity with the disease course of cancer patients remains controversial. Although adiposity seems to be positively correlated with OS in several solid tumors \[[@pone.0228360.ref016], [@pone.0228360.ref017]\], poorer survival figures have been reported for obese patients with cancer--possibly because of an increased production of growth factors and inflammatory mediators from the adipose tissue.\[[@pone.0228360.ref018]\] In this regard, it should be noted that adipose tissue may serve as a nutrient replacement in patients with cancer, \[[@pone.0228360.ref015], [@pone.0228360.ref019]\] but it can be also involved in tumor spread through adipokine-induced extracellular matrix remodeling.\[[@pone.0228360.ref020]\]

Pai et al. \[[@pone.0228360.ref021]\] have previously shown that SATI is strongly related to distant metastasis-free survival, locoregional control, and OS in 881 patients with head and neck cancer. Ebadi et al. \[[@pone.0228360.ref005]\] also demonstrated that patients with low SATI and high VATI independently predicted mortality in a sample of patients with different solid malignancies. Herein, we show that VATI, and most prominently SATI, were significantly associated with OS in Taiwanese patients with bone metastases. Controversy still exists on the relationship between VATI and clinical outcomes in patients with solid tumors.\[[@pone.0228360.ref010], [@pone.0228360.ref022]--[@pone.0228360.ref024]\] The reasons whereby SATI appears to hold a stronger association with OS over VATI in our study remain to be elucidated. However, it is notable that--differently from visceral fat (which is an active endocrine organ)--subcutaneous fat is more strictly involved in lipid and energy storage and is characterized by a lower inflammatory environment \[[@pone.0228360.ref014], [@pone.0228360.ref025], [@pone.0228360.ref026]\].

The study was conducted in a radiation oncology setting. Bone metastases are not only the most common site of distant spread in patients with solid malignancies but they are also the most commonly identified by radiation oncologists. The question as to whether our findings may be applied to patients with metastases to other distant sites (e.g., liver or brain) remains open. We acknowledge several limitations of the present study. First, the study was conducted in an Asian population, and it is well-known that ethnic differences exist in measures of adiposity between Asian and Caucasian populations \[[@pone.0228360.ref027]\]. Therefore, our findings need to be independently replicated in other geographic areas. Second, we did not segment body fat in the whole CT volume. Nonetheless, there is published evidence suggesting that measures of adiposity obtained at the L3 level through a simplified CT protocol are well-correlated to those taken at other sites \[[@pone.0228360.ref028]--[@pone.0228360.ref031]\]. Third, all measures of adiposity were taken in the two week preceding the start of RT. Wu et al. \[[@pone.0228360.ref032]\] have recently demonstrated the prognostic importance of the time at which body adiposity is assessed. However, these data were not available in this study, and we were unable to run this analysis. Finally, this was a retrospective analysis of prospectively collected data which had an exploratory nature. The application of the Bonferroni's correction in this setting may be too conservative and was avoided. In any case, our results should be considered as preliminary and hypothesis-generating. Because we observed associations, we cannot claim any prognostic effect of adiposity indices in our population. Future longitudinal studies are required to clarify this issue further.

These limitations notwithstanding, we found that high SATI and VATI are associated with a more favorable OS in Taiwanese patients with bone metastases referred for RT. The question as to whether clinical measures aimed at improving adiposity may improve OS in this clinical population deserves further scrutiny.

The authors thank all the patients for the participation in this study.

10.1371/journal.pone.0228360.r001
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AUTHORS' REPLY TO REVIEWER'S \#1 COMMENTS

1\. The association between body fat and survival in many cancers is well-known and established. Hence, the study does not add much new to the current knowledge. However, I acknowledge that this is not necessarily relevant for PLoS ONE, so this point may be disregarded by the editor.

REPLY. We thank the Reviewer for the constructive criticism. We concur that the association between adiposity and survival in patients with malignancies has been extensively investigated in the past. However, this study may represent a valid addition to the existing literature for the following reasons: 1) the association of subcutaneous adiposity and visceral adiposity with survival endpoints in patients with cancer remains controversial, 2) we specifically focused on patients with bone metastases who were referred for radiotherapy (see below for further clarifications on study population); 3) the study was conducted in an Asian population (it is well-known that ethnic differences exist in measures of adiposity between Asian and Caucasian populations). We believe that these points should be considered when dealing with the novelty of our work. Please note that the title has been revised to highlight the ethnic origin of the study population.

The study rationale is not quite clear. Why focus on patients with bone metastases? Other metastases also herald poor prognosis (liver, brain \...).

REPLY. We are grateful to the Reviewer for the cogent comment. We specifically focused on bone metastases for the following reasons. First, the study was conducted in a radiation oncology setting. Bone metastases are not only the most common site of distant spread in patients with solid malignancies but they are also the most commonly identified by radiation oncologists. We did focus on bone metastases not only because they portend a poor prognosis, but also in light of their high frequency. Second, patients with bone metastases commonly present with pain and an impaired quality of life, ultimately requiring referral for radiotherapy. We therefore believe that our study population is of special interest for radiation therapists. We nonetheless acknowledged the lack of inclusion of patients with metastases at other sites as a limitation inherent in our study (please see the revised "Discussion" section).

The chance was missed to segment the body fat in the whole CT scan volume and thus provide a more accurate estimate.

REPLY. We concur with the Reviewer that whole-body computed tomography (CT) can actually provide a more accurate and comprehensive estimation of adiposity. However, there is published evidence (see references 1−4 below) suggesting that measures of adiposity obtained at the L3 level through a simplified CT protocol are well-correlated to those taken at other sites. We are aware that this is a potential limitation inherent in our study, which has been acknowledged in the revised "Discussion" section.

A biostatistician should be consulted for the statistical analysis, which is not well done (the current analysis leads to spuriously low p-values).

REPLY. This study was designed as a retrospective analysis of prospectively collected data (a point which has been clarified in revised paper). The statistical approach was in line with the analyses conducted in other published papers from our group (see references 5−8 below). With regard to the low p-values, they may stem from a multiple comparison problem. However, the application of the Bonferroni's correction may be too conservative in an exploratory analysis. We nonetheless believe that this is a potential caveat inherent in our study, which has been addressed in the revised "Discussion" section.

5\. The term \"predictor\" should be avoided throughout the manuscript. In a retrospective study, one can only find associations. Predictions can only be made with a prospective trial. This leads me to the next point

REPLY. We thank the Reviewer for the pertinent observation. In the revised version of the paper, we made appropriate revisions to highlight that we observed associations, not prediction or causation. We also acknowledged the retrospective design as a major study limitation in the "Discussion" section.

6\. The authors grossly overinterpret the results of their study. Although this is unfortunately the norm in many scientific journals where authors need to \"sell\" their study, per PLoS ONE policy this is not needed. To give the authors an example: \"More importantly, our findings may pave the way for aggressive therapeutic interventions in the subset of patients who are expected to have more favorable survival figures\" To make such a statement, a prospective randomised clinical trial is needed.

REPLY. The Reviewer is entirely right and we apologize for the excessive emphasis put on the significance of our findings. In the revised version of the paper, several statements were toned down, the main limitations were highlighted, and the conclusions were drawn more prudently. We have highlighted these points as a relevant future research topic in the revised "Discussion" section.
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AUTHORS' REPLY TO REVIEWER'S \#2 COMMENTS

On page 25, the authors report as a limitation of this study: \"Body composition was assessed in all patients prior to the first RT session and not when bone metastases were diagnosed.\" However, they do not clearly explain how this may imply the results found. Thus, I suggest to the authors, as a minor review, to further clarify this issue, given that the time when BMI was determined is relevant to the observed patterns of association.

We suggest the authors review the World Cancer Research Fund (WCRF) report on the effect of risk factors on survival among women with breast cancer. This recent report added a very useful classification---namely, determination of BMI either at pre-, peri-, or post-diagnosis (the later typically 12 months after the initial treatment) of câncer. From these, different patterns of associations emerge. In a meta-analysis of 29 studies evaluating the impact of BMI on survival in patients with colorectal cancer, Wu et al. observed that increasing pre-diagnosis BMI prognosticated for a poor survival but that post-treatment overweight was associated with improved survival, i.e., the obesity paradox.
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REPLY. We thank the Reviewer for the constructive observations. In the revised version of the paper, we clarified that all measures of adiposity were taken in the two week preceding the start of RT. With regard to the World Cancer Research Fund (WCRF) report and the paper by Wu et al., we realize the prognostic importance of the time at which body adiposity is assessed. However, these data were not available in this study, and we were therefore unable to run this analysis. We have highlighted this point as a relevant future research topic in the revised "Discussion" section.

We had mentioned in the Discussion line 256: "Fourth, all measures of adiposity were taken in the two week preceding the start of RT. Wu et al. (32) have recently demonstrated the prognostic importance of the time at which body adiposity is assessed. However, the data of post-diagnosis of cancer (12 months after initial treatment) were not available in this study, and we were unable to run this analysis. "

AUTHORS' REPLY TO REVIEWER'S \#3 COMMENTS

I consider the piece is valuable. However, results must be explained more in detail to be able to trace interpretations offered at discussion. Manuscript should be reviewed for grammatical errors (for example patient demographics, should be more in relation to the concept assessment than the way variables were implemented), specially for critical interpretations of data and analyses. Recommendations for more aggressive therapeutics is not included in the analysis, but is being offered as a conclusion, therefore I recommend to review this issue and explain more about how this is derived from the analysis.

REPLY. We thank the Reviewer for the constructive criticisms. In order to address the concern, the following changes were implemented: 1) the paper has been revised for style and presentation; 2) the nature of the analysis was clarified (retrospective analysis of prospectively collected data) and any reference to prediction or causation were removed; 3) we removed the emphasis on therapeutic recommendations because we realize that they are unwarranted based on our current data.
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